Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
ONTAK is a biologic therapeutic approved in 1999 as a vial formulation under Biologics License Application. The specific indication and mechanism of action are not publicly detailed in available data, limiting full characterization of its clinical role.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting shrinking team and focus on generic transition or lifecycle extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Vaccination Plus Ontak in Patients With Metastatic Melanoma
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Worked on ONTAK at Eisai? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ONTAK has zero linked job postings, reflecting its LOE status and mature market position. Roles on this product focus on market preservation and generic transition rather than growth, offering limited career momentum.